# RISA Labs Advisory Board Design & Parker Institute Classification

*Research compiled 2026-02-20*

---

## Task 1: RISA Labs Advisory Board (5 Seats)

RISA Labs is an oncology-focused AI operating system company ($11.1M Series A) targeting patient access, RCM, clinical decision support, and life sciences. The advisory board should give them credibility with cancer center executives, pharma, investors, and regulators.

---

### Seat 1: Oncology Clinical Leader

**Role:** Practicing or recently-practicing oncology leader from a major cancer center. Validates clinical AI credibility.

**Ideal Profile:** Medical oncologist with administrative leadership (CMO, Division Chief, or Cancer Center Director) at an NCI-designated cancer center. Deep understanding of treatment workflows, prior auth burden, and clinical decision support needs.

**Suggested Names:**

1. **Robert Carlson, MD** ‚Äî Former CEO, National Comprehensive Cancer Network (NCCN)
   - *Why:* NCCN literally writes the clinical guidelines RISA encodes into its intelligence layer. Having NCCN leadership validates clinical rigor. Recently stepped down as CEO ‚Äî likely available.
   - *Reachability:* High. Active in advisory roles post-NCCN. Frequently speaks at ASCO/HIMSS.

2. **Tatjana Kolevska, MD** ‚Äî Medical Director, Kaiser Permanente National Cancer Program
   - *Why:* Operates at the intersection of clinical oncology and integrated health system operations. Understands both clinical workflows and system-level efficiency.
   - *Reachability:* Medium. Active in quality/pathway work.

3. **Andrew Zelenetz, MD, PhD** ‚Äî Vice Chair, Medical Informatics, Memorial Sloan Kettering
   - *Why:* MSK + informatics focus = perfect overlap with clinical AI. Understands EHR integration, clinical decision support in oncology.
   - *Reachability:* Medium. On multiple guideline committees.

4. **Debra Patt, MD, PhD, MBA** ‚Äî Executive VP, Texas Oncology (RISA's existing client)
   - *Why:* Already in RISA's orbit. Community oncology leader, policy advocate, wrote a book on healthcare AI. VP of Texas Oncology ‚Äî one of the largest community oncology practices.
   - *Reachability:* High. Very active in health IT/policy. Already connected to RISA ecosystem.

5. **Erica Mayer, MD, MPH** ‚Äî Senior VP, Clinical Cancer Research, Dana-Farber
   - *Why:* Research + clinical operations lens at a top cancer center. Strong trials background relevant to life sciences AI.
   - *Reachability:* Medium.

**üèÜ Top Pick: Debra Patt** ‚Äî existing relationship, community oncology credibility, policy voice, health IT expertise. Second choice: Robert Carlson for NCCN guideline authority.

---

### Seat 2: Health System CFO / Revenue Cycle Executive

**Role:** Senior finance or revenue cycle operations leader who can validate the RCM AI and patient access value proposition. Speaks the language of cancer center CFOs.

**Ideal Profile:** CFO, VP Revenue Cycle, or VP Operations at a large health system or cancer center network. Deep expertise in oncology billing complexity (drug costs, buy-and-bill, prior auth, denials).

**Suggested Names:**

1. **Daniel Morhaim, MD** ‚Äî Former SVP & Chief Medical Officer of Revenue Cycle, Optum
   - *Why:* Combined clinical + RCM expertise at massive scale. Understands payer-provider dynamics from the inside.
   - *Reachability:* Medium-High. Active in consulting/advisory.

2. **Zirui Song, MD, PhD** ‚Äî Associate Professor, Harvard Medical School; former advisor to CMS
   - *Why:* Health economics researcher, CMS policy experience. Can speak to value-based care and oncology payment models (OCM, EOM).
   - *Reachability:* Medium. Academic, but policy-connected.

3. **Keely Macmillan** ‚Äî SVP Revenue Cycle, Providence Health
   - *Why:* Runs revenue cycle for one of the largest health systems in the US. Operational credibility.
   - *Reachability:* Medium. Operational leader, less advisory-circuit visible.

4. **Joe Damore** ‚Äî VP, Premier Inc. (healthcare performance improvement)
   - *Why:* Works across hundreds of health systems on financial performance and operational efficiency.
   - *Reachability:* High. Consulting/advisory role already.

5. **Shawn Filippi** ‚Äî Former CFO, City of Hope
   - *Why:* CFO of a major NCI-designated cancer center. Understands oncology-specific financial operations.
   - *Reachability:* High if recently transitioned.

**üèÜ Top Pick: Someone with oncology-specific CFO/RCM experience.** Debra Patt (Seat 1) partially covers this given her MBA and Texas Oncology operations role. For a pure finance seat, target a cancer center CFO or a revenue cycle VP from a large oncology network.

---

### Seat 3: AI/ML Research Leader

**Role:** Technical AI credibility. A recognized name in healthcare AI/ML ‚Äî ideally someone publishing in the intersection of AI, oncology, and clinical operations.

**Ideal Profile:** Professor or industry research leader in biomedical AI, clinical NLP, or health informatics. Publications in top venues (Nature Medicine, JAMA, NeurIPS Health).

**Suggested Names:**

1. **Andrew Ng, PhD** ‚Äî Founder, DeepLearning.AI; Adjunct Professor, Stanford
   - *Why:* Global AI brand recognition. Stanford Healthcare AI work. Would be a massive credibility signal to investors.
   - *Reachability:* Low. Very selective, but not impossible for board seats at interesting companies.

2. **Fei-Fei Li, PhD** ‚Äî Co-Director, Stanford Human-Centered AI Institute (HAI)
   - *Why:* AI luminary. Healthcare AI focus. Stanford connection overlaps with Stanford Cancer Center relationship.
   - *Reachability:* Low. Very high-profile.

3. **Nigam Shah, MBBS, PhD** ‚Äî Chief Data Scientist, Stanford Medicine; Professor of Biomedical Data Science
   - *Why:* Directly works on clinical AI deployment at Stanford Medicine. Practical, not just theoretical. Published extensively on clinical NLP and decision support.
   - *Reachability:* Medium. Already advises health AI companies. Excellent fit.

4. **Isaac Kohane, MD, PhD** ‚Äî Chair, Department of Biomedical Informatics, Harvard Medical School
   - *Why:* Pioneer in clinical informatics and AI in medicine. Credibility with both academic and industry audiences.
   - *Reachability:* Medium. Active advisor.

5. **Atul Butte, MD, PhD** ‚Äî Director, Bakar Computational Health Sciences Institute, UCSF
   - *Why:* Translational bioinformatics leader. Focus on moving computational methods into clinical practice. UCSF connection.
   - *Reachability:* Medium. On multiple boards already.

**üèÜ Top Pick: Nigam Shah** ‚Äî most practical fit (Stanford Medicine, clinical AI deployment, accessible). If aiming for bigger brand: Isaac Kohane or Atul Butte.

---

### Seat 4: Life Sciences / Pharma Leader

**Role:** Validates the life sciences AI play (real-world evidence, pharma partnerships, clinical trials). Opens doors to pharma commercial teams and R&D.

**Ideal Profile:** Former VP+ at a major pharma or biotech, focused on oncology commercial, real-world evidence, or clinical development. Alternatively, a leader from an oncology-focused CRO or RWE platform.

**Suggested Names:**

1. **Roy Baynes, MD, PhD** ‚Äî Former SVP & Head of Global Clinical Development, Chief Medical Officer, Merck (Keytruda architect)
   - *Why:* Oversaw the clinical development of Keytruda ‚Äî the world's top-selling cancer drug. Massive pharma credibility. Understands what pharma needs from real-world data and AI-driven evidence.
   - *Reachability:* Medium-High. Recently transitioned from Merck. Likely seeking board/advisory roles.

2. **Amy Abernethy, MD, PhD** ‚Äî Former Principal Deputy Commissioner, FDA; Former CMO, Flatiron Health
   - *Why:* Unique trifecta: FDA (regulatory), Flatiron (oncology data/AI), clinical oncology. Understands RWE, regulatory, and oncology AI deeply.
   - *Reachability:* Medium. Very in-demand. Currently at Verily/Google Health ecosystem.

3. **Jeff Allen, PhD** ‚Äî President & CEO, Friends of Cancer Research
   - *Why:* Policy bridge between FDA, pharma, and cancer centers. Focused on accelerating approval pathways.
   - *Reachability:* Medium-High.

4. **Mace Rothenberg, MD** ‚Äî Former Chief Development Officer, Pfizer Oncology
   - *Why:* Led Pfizer's entire oncology development pipeline. Deep pharma oncology expertise.
   - *Reachability:* High. Active in advisory/board roles post-Pfizer.

5. **Gideon Blumenthal, MD** ‚Äî Former Acting Director, FDA Oncology Center of Excellence
   - *Why:* FDA oncology regulatory perspective. Understands what evidence FDA needs ‚Äî directly relevant to RISA's clinical AI and RWE capabilities.
   - *Reachability:* Medium-High.

**üèÜ Top Pick: Amy Abernethy** ‚Äî the dream candidate (FDA + Flatiron + oncology). She's in high demand though. Realistic alternative: Mace Rothenberg or Roy Baynes for pure pharma credibility.

---

### Seat 5: Health Policy / Payer / Regulatory

**Role:** Validates compliance, payer relationships, and regulatory navigation. Critical for prior auth AI, payer policy encoding, and CMS/commercial payer credibility.

**Ideal Profile:** Former CMS official, payer CMO, or health policy leader with oncology experience. Understands prior authorization reform, oncology payment models (OCM/EOM), and value-based care.

**Suggested Names:**

1. **Lee Newcomer, MD, MHA** ‚Äî Former SVP, UnitedHealthcare Oncology
   - *Why:* Ran oncology strategy for the largest US payer. Designed oncology payment models. Understands prior auth, medical policy, and payer-provider friction intimately.
   - *Reachability:* High. Retired/advisory mode. Active speaker and consultant. Perfect fit.

2. **Mark McClellan, MD, PhD** ‚Äî Director, Duke-Margolis Center for Health Policy; Former FDA Commissioner & CMS Administrator
   - *Why:* Ran both FDA and CMS. Ultimate regulatory/policy credibility. Focused on value-based care and innovation.
   - *Reachability:* Medium. Very high profile but takes select advisory roles.

3. **Dora Hughes, MD, MPH** ‚Äî Former HHS senior advisor; health policy expert
   - *Why:* Senior government health policy experience. Focus on access and coverage.
   - *Reachability:* Medium-High.

4. **Karen DeSalvo, MD, MPH, MSc** ‚Äî Chief Health Officer, Google; Former National Coordinator for Health IT (ONC)
   - *Why:* ONC + Google Health. Understands health IT policy, interoperability, and AI regulation.
   - *Reachability:* Low-Medium. Currently at Google.

5. **Kavita Patel, MD, MS** ‚Äî Nonresident Fellow, Brookings; Former Obama White House health policy advisor
   - *Why:* Health policy with a practicing clinician's lens. Prior auth reform advocate.
   - *Reachability:* Medium-High. Active in advisory work.

**üèÜ Top Pick: Lee Newcomer** ‚Äî perfectly positioned for RISA's payer/prior auth play. Has the exact domain expertise (oncology payer strategy) that RISA's customers care about.

---

### Summary: Recommended Dream Board

| Seat | Role | Top Pick | Backup |
|------|------|----------|--------|
| 1 | Oncology Clinical Leader | **Debra Patt, MD** (Texas Oncology) | Robert Carlson, MD (ex-NCCN) |
| 2 | Health System Finance/RCM | **Cancer Center CFO** (target specific) | Zirui Song, MD, PhD (Harvard/CMS) |
| 3 | AI/ML Research | **Nigam Shah, PhD** (Stanford Medicine) | Atul Butte, MD, PhD (UCSF) |
| 4 | Life Sciences/Pharma | **Amy Abernethy, MD, PhD** (ex-FDA/Flatiron) | Mace Rothenberg, MD (ex-Pfizer) |
| 5 | Health Policy/Payer | **Lee Newcomer, MD** (ex-UnitedHealthcare) | Mark McClellan, MD, PhD (Duke) |

**Credibility this board delivers:**
- **Cancer center executives:** Patt (Texas Oncology insider) + Newcomer (payer side they negotiate with)
- **Pharma/life sciences:** Abernethy (FDA/RWE gold standard) + Rothenberg backup
- **Investors:** Shah or Butte (Stanford/UCSF AI brand) + Abernethy (Flatiron exit = investor catnip)
- **Regulatory/compliance:** Newcomer (payer policy) + Abernethy (FDA) + McClellan backup (FDA + CMS)

---

## Task 2: Parker Institute for Cancer Immunotherapy ‚Äî Classification

### What Is PICI?

The Parker Institute for Cancer Immunotherapy (PICI) is a **research coordination and funding organization** ‚Äî not a hospital, not a traditional research institute, and not a clinical care provider.

- **Founded:** April 2016
- **Founder:** Sean Parker (Napster co-founder, Facebook early investor) via the Parker Foundation
- **Initial funding:** $250 million grant
- **Location:** San Francisco (administrative HQ)
- **President:** Karen E. Knudsen, PhD
- **President of Research:** Ira Mellman, PhD (former VP Cancer Immunology, Genentech)

### How PICI Works

PICI is a **networked research accelerator**. It does not:
- ‚ùå Treat patients directly
- ‚ùå Operate hospitals or clinics
- ‚ùå Run its own wet labs (in the traditional sense)

It does:
- ‚úÖ Fund immunotherapy research across 7 elite partner institutions
- ‚úÖ Coordinate multi-site collaborative research
- ‚úÖ Remove IP/data-sharing barriers between institutions
- ‚úÖ Spin out companies (e.g., Dispatch Bio for solid tumors)
- ‚úÖ Award grants to early-career researchers
- ‚úÖ Collaborate with organizations like ASCO/Conquer Cancer

**Partner Network:**
Stanford Medicine, UCLA, UCSF, UPenn, Dana-Farber, Gladstone Institutes, Weill Cornell Medicine

### How PICI Differs from Major Cancer Centers

| | PICI | MD Anderson | MSK | Fred Hutch |
|---|---|---|---|---|
| **Type** | Research funder/coordinator | Comprehensive cancer center | Comprehensive cancer center | Cancer research center + clinical |
| **Treats patients?** | No | Yes (huge volume) | Yes | Yes |
| **Runs labs?** | Via partner institutions | Yes (own labs) | Yes (own labs) | Yes (own labs) |
| **NCI designation?** | No | NCI Comprehensive | NCI Comprehensive | NCI Comprehensive |
| **Funding model** | Philanthropic (Parker Foundation) | NIH + patients + philanthropy + state | NIH + patients + philanthropy | NIH + patients + philanthropy |
| **Focus** | Immunotherapy only | All cancers, all modalities | All cancers, all modalities | Cancer + infectious disease |
| **Staff scientists?** | Minimal ‚Äî works through network | Thousands | Thousands | Thousands |

### Taxonomy of Cancer Institution Types

**1. NCI-Designated Comprehensive Cancer Centers** (71 in US)
- *Examples:* MD Anderson, Memorial Sloan Kettering, Dana-Farber, Fred Hutch, Mayo Clinic
- *Model:* Full-service: research + clinical care + education + community outreach
- *Funding:* NIH/NCI grants + clinical revenue + philanthropy

**2. Freestanding Cancer Research Institutes**
- *Examples:* Salk Institute (cancer biology), Cold Spring Harbor (cancer genetics)
- *Model:* Pure research, no or minimal patient care
- *Funding:* NIH + philanthropy

**3. Philanthropic Research Accelerators / Networked Funders** ‚Üê **PICI is here**
- *Examples:* **Parker Institute (PICI)**, Mark Foundation for Cancer Research, Stand Up To Cancer (SU2C), V Foundation
- *Model:* Fund and coordinate research across partner institutions. Don't operate labs or treat patients directly. Focus on removing barriers to collaboration.
- *Funding:* Major philanthropy (billionaire/celebrity-backed)
- *Distinguishing feature:* PICI is more operationally involved than a pure grant-maker ‚Äî they describe themselves as "an active research institute" that coordinates across sites and manages IP/data sharing.

**4. Cancer-Focused Advocacy & Funding Organizations**
- *Examples:* American Cancer Society, Leukemia & Lymphoma Society, Pancreatic Cancer Action Network
- *Model:* Fundraising, patient support, research grants, policy advocacy
- *Funding:* Public donations, events

**5. Government Cancer Agencies**
- *Examples:* National Cancer Institute (NCI), ARPA-H (cancer moonshot programs)
- *Model:* Federal research funding and coordination
- *Funding:* Congressional appropriation

**6. Cancer-Focused Biotech/Industry**
- *Examples:* Flatiron Health (oncology data), Foundation Medicine (genomic testing), Tempus (precision medicine)
- *Model:* Commercial entities serving the cancer ecosystem
- *Funding:* Venture capital + revenue

### Where PICI Fits ‚Äî Summary

PICI is best classified as a **philanthropic research accelerator with an active coordination model**. It sits between a pure grant-maker (like the V Foundation) and an actual research institute (like Fred Hutch). Its innovation is structural: using Sean Parker's $250M to break down the IP, data-sharing, and collaboration barriers that slow immunotherapy research across elite institutions.

Think of it as: **DARPA for cancer immunotherapy** ‚Äî it doesn't do the research itself, but it funds, coordinates, and removes friction so the research happens faster across its network.
